Le Lézard15m
Genentech's Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson's Disease
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson's ...
Le Lézard45m
HOME AFFORDABILITY WORSENS AGAIN ACROSS U.S. IN FOURTH QUARTER AS HOME PRICES KEEP CLIMBING
ATTOM, a leading curator of land, property data, and real estate analytics, today released its fourth-quarter 2024 U.S. Home Affordability Report showing that median-priced single-family homes and ...
Indiatimes on MSN15m
Apple may not ever sell iPhones on subscriptions
Apple has scrapped its plans for an iPhone hardware subscription service, according to Bloomberg. The program, under ...